Skip to main content

Table 1 Phase II studies incorporating targeted agents in advanced gastroesophageal cancer

From: Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology

Targeted agent Chemotherapy N RR PFS (months) OS (months) Reference
Cetuximab Irinotecan and FU 49 42% 8.6 16.6 Kanzler et al. [11]
Bevacizumab Docetaxel, FU and cisplatin 44 67% 12 16.2 Kelsen et al. [12]
Cetuximab Irinotecan and oxaliplatin 51 60% 6 9.5 Woell et al. [13]
  1. N: patient number; RR: response rate; PFS: progression-free survival; OS: overall survival; FU: 5-fluorouracil